Mainstream

Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone

Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone

Post ContenthrtxRead More

You might also be interested in reading Standard Chartered debuts crypto services in Europe with new license.

August 8, 2025
In Mainstream